• Je něco špatně v tomto záznamu ?

Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication

H. Paul, V. Berg, B. Gangadharan, J. Bowen, P. LeBeau, J. Blatný, C. Male, VC. Radulescu, R. Diaz, ME. Mancuso, DL. Brown, BM. Reipert

. 2023 ; 7 (9) : 1831-1848. [pub] 2023May09

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23011469

Factor VIII (FVIII) inhibitor formation is a major clinical concern during replacement therapy in patients with hemophilia A. Immune tolerance induction (ITI) is the only therapeutic approach to attempt inhibitor eradication and establishment of long-term immune tolerance to FVIII. Hemophilia Inhibitor Previously Untreated Patient (PUP) Study (HIPS) was a prospective clinical trial to investigate changes in the immune system of PUPs with severe hemophilia A. Five patients who developed persistent FVIII inhibitors during HIPS entered an ITI extension arm (HIPS-ITI). During HIPS-ITI, inhibitor patients received ITI with the same FVIII product (a single source of recombinant, human full-length FVIII) used in HIPS until successful tolerance, declared failure, or a maximum of 2 years after HIPS-ITI enrollment, whichever came first. Blood samples and clinical data were collected monthly. Longitudinal FVIII-binding antibody signatures, associated binding specificities, and apparent affinities were determined for each patient at each sampling time point. ITI was successful or partially successful in 2 patients and failed in 3. Both groups presented with distinct FVIII-specific antibody signatures. ITI success required the disappearance of FVIII inhibitors, which was associated with the eradication or sustained titer minimization of high-affinity FVIII-specific antibodies, particularly of the immunoglobulin G1 (IgG1) and IgG4 subclasses. In contrast, ITI failure, as reflected by FVIII inhibitor persistence, was associated with persistent high-affinity FVIII-specific antibodies. Interestingly, 1 patient with partial ITI success and 1 patient with ITI failure developed apparent oligoreactive FVIII-binding antibodies during ITI. The explanation of the true nature of these antibodies requires more comprehensive follow-ups in future studies. This trial was registered at www.clinicaltrials.gov as #NCT01652027.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011469
003      
CZ-PrNML
005      
20230801133052.0
007      
ta
008      
230718s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/bloodadvances.2022007267 $2 doi
035    __
$a (PubMed)36074992
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Paul, Helmut $u Institute Krems Bioanalytics, IMC University of Applied Sciences Krems, Krems, Austria $1 https://orcid.org/0000000332174454
245    10
$a Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication / $c H. Paul, V. Berg, B. Gangadharan, J. Bowen, P. LeBeau, J. Blatný, C. Male, VC. Radulescu, R. Diaz, ME. Mancuso, DL. Brown, BM. Reipert
520    9_
$a Factor VIII (FVIII) inhibitor formation is a major clinical concern during replacement therapy in patients with hemophilia A. Immune tolerance induction (ITI) is the only therapeutic approach to attempt inhibitor eradication and establishment of long-term immune tolerance to FVIII. Hemophilia Inhibitor Previously Untreated Patient (PUP) Study (HIPS) was a prospective clinical trial to investigate changes in the immune system of PUPs with severe hemophilia A. Five patients who developed persistent FVIII inhibitors during HIPS entered an ITI extension arm (HIPS-ITI). During HIPS-ITI, inhibitor patients received ITI with the same FVIII product (a single source of recombinant, human full-length FVIII) used in HIPS until successful tolerance, declared failure, or a maximum of 2 years after HIPS-ITI enrollment, whichever came first. Blood samples and clinical data were collected monthly. Longitudinal FVIII-binding antibody signatures, associated binding specificities, and apparent affinities were determined for each patient at each sampling time point. ITI was successful or partially successful in 2 patients and failed in 3. Both groups presented with distinct FVIII-specific antibody signatures. ITI success required the disappearance of FVIII inhibitors, which was associated with the eradication or sustained titer minimization of high-affinity FVIII-specific antibodies, particularly of the immunoglobulin G1 (IgG1) and IgG4 subclasses. In contrast, ITI failure, as reflected by FVIII inhibitor persistence, was associated with persistent high-affinity FVIII-specific antibodies. Interestingly, 1 patient with partial ITI success and 1 patient with ITI failure developed apparent oligoreactive FVIII-binding antibodies during ITI. The explanation of the true nature of these antibodies requires more comprehensive follow-ups in future studies. This trial was registered at www.clinicaltrials.gov as #NCT01652027.
650    _2
$a lidé $7 D006801
650    12
$a hemofilie A $x terapie $7 D006467
650    _2
$a prospektivní studie $7 D011446
650    _2
$a faktor VIII $x terapeutické užití $7 D005169
650    12
$a hemostatika $x terapeutické užití $7 D006490
650    _2
$a imunologická tolerance $7 D007108
650    _2
$a imunoglobulin G $x terapeutické užití $7 D007074
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Berg, Verena $u Institute Krems Bioanalytics, IMC University of Applied Sciences Krems, Krems, Austria $1 https://orcid.org/0000000332462317
700    1_
$a Gangadharan, Bagirath $u Baxalta Innovations GmbH, Vienna, Austria
700    1_
$a Bowen, Joel $u Indiana Hemophilia and Thrombosis Center Inc., Indianapolis, IN
700    1_
$a LeBeau, Petra $u Rho Inc., Durham, NC
700    1_
$a Blatný, Jan $u Department of Paediatric Haematology, University Hospital Brno, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000162619157 $7 xx0034546
700    1_
$a Male, Christoph $u Department of Pediatrics, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000249896421
700    1_
$a Radulescu, Vlad C $u Hemophilia Treatment Center, University of Kentucky, Lexington, KY $1 https://orcid.org/0000000183385185
700    1_
$a Diaz, Rosa $u Baylor College of Medicine, Houston, TX
700    1_
$a Mancuso, Maria Elisa $u IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy $u Fondazione Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy $1 https://orcid.org/0000000271134028
700    1_
$a Brown, Deborah L $u University of Texas Health Science Center, Houston, TX $1 https://orcid.org/0000000152320477
700    1_
$a Reipert, Birgit M $u Institute Krems Bioanalytics, IMC University of Applied Sciences Krems, Krems, Austria $u Baxalta Innovations GmbH, Vienna, Austria $1 https://orcid.org/0000000174554610
773    0_
$w MED00194912 $t Blood advances $x 2473-9537 $g Roč. 7, č. 9 (2023), s. 1831-1848
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36074992 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133049 $b ABA008
999    __
$a ok $b bmc $g 1963715 $s 1197734
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 7 $c 9 $d 1831-1848 $e 2023May09 $i 2473-9537 $m Blood advances $n Blood Adv $x MED00194912
LZP    __
$a Pubmed-20230718
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace